Newron presents H1 2024 results and provides business update

Newron Pharmaceuticals reports on its 2024 Investor Day in New York City

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City

Save the Date: June 25, Newron Investor Day: Evenamide for poor responders and patients with treatment-resistant Schizophrenia, a Roadmap to Registration

Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients

Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients

Newron announces AGM 2024 results

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Invitation to attend the General Meeting

Pagination